[go: up one dir, main page]

HRP20200551T1 - Axl-specifični konjugati protutijelo-lijek za liječenje raka - Google Patents

Axl-specifični konjugati protutijelo-lijek za liječenje raka Download PDF

Info

Publication number
HRP20200551T1
HRP20200551T1 HRP20200551TT HRP20200551T HRP20200551T1 HR P20200551 T1 HRP20200551 T1 HR P20200551T1 HR P20200551T T HRP20200551T T HR P20200551TT HR P20200551 T HRP20200551 T HR P20200551T HR P20200551 T1 HRP20200551 T1 HR P20200551T1
Authority
HR
Croatia
Prior art keywords
adc
use according
antibody
cancer
region
Prior art date
Application number
HRP20200551TT
Other languages
English (en)
Inventor
Julia BOSHUIZEN
Kirstine JACOBSEN
Esther BREIJ
Louise KOOPMAN
David Satijn
Edward Van Den Brink
Dennis VERZIJL
Rob DE JONG
Riemke VAN DIJKHUIZEN RADERSMA
Daniel PEEPER
Henrik Jørn DITZEL
Paul Parren
Original Assignee
Genmab A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2015/065900 external-priority patent/WO2016005593A1/en
Application filed by Genmab A/S filed Critical Genmab A/S
Publication of HRP20200551T1 publication Critical patent/HRP20200551T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (37)

1. Konjugat protutijelo-lijek (ADC - engl. antibody-drug conjugate), naznačen time, da obuhvaća protutijelo koje se veže na ljudski AXL i služi za liječenje raka koji je otporan na najmanje jedno terapeutsko sredstvo odabrano iz skupine koja se sastoji od sljedećih: inhibitor kinaze tirozina, inhibitor kinaze serina/treonina, i kemoterapeutsko sredstvo, pri čemu ADC obuhvaća najmanje jedno područje vezanja koje sadrži VH područje sa sekvencama CDR1, CDR2 i CDR3 od SEQ ID br. 36, 37 odnosno 38, za pojedino CD-područje; te VL područje sa sekvencama CDR1, CDR2 i CDR3 od SEQ ID br. 39, GAS odnosno 40, za pojedino CD-područje.
2. ADC za uporabu prema patentnom zahtjevu 1, naznačen time, da je inhibitor kinaze tirozina odabran iz skupine koja se sastoji od sljedećih: erlotinib, afatinib, gefitinib, lapatinib, osimertinib, rociletinib, imatinib, sunitinib, krizotinib, midostaurin (PKC412) i kvizartinib (AC220).
3. ADC za uporabu prema patentnom zahtjevu 1, naznačen time, da je inhibitor kinaze serina/treonina BRAF-inhibitor ili MEK-inhibitor.
4. ADC za uporabu prema patentnom zahtjevu 3, naznačen time, da: (a) BRAF-inhibitor je odabran iz skupine koja se sastoji od sljedećih: vemurafenib (PLX4032), dabrafenib, te terapeutski djelotvoran analog ili derivat od bilo kojega od njih, primjerice PLX4720; (b) MEK-inhibitor je odabran iz skupine koja se sastoji od sljedećih: trametinib i selumetinib (AZD6244), te terapeutski djelotvoran analog ili derivat od bilo kojega od njih.
5. ADC za uporabu prema patentnom zahtjevu 1, naznačen time, da je kemoterapeutsko sredstvo odabrano iz skupine koja se sastoji od sljedećih: paklitaksel, docetaksel, cisplatin, metformin, doksorubicin, etopozid, karboplatin ili njihove kombinacije.
6. ADC za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da: (a) inhibitor kinaze tirozina je odabran od antagonista receptora epidermalnog faktora rasta (EGFR - engl. epidermal growth factor receptor), HER2-antagonista, ALK-inhibitora i FLT3-inhibitora, ili od kombinacije bilo kojega od njih; (b) inhibitor kinaze serina/treonina je odabran od BRAF-inhibitora i MEK-inhibitora, ili od njihove kombinacije; (c) kemoterapeutsko sredstvo je odabrano od sljedećih: paklitaksel, docetaksel, cisplatin, metformin, doksorubicin, etopozid, karboplatin ili njihova kombinacija.
7. ADC za uporabu prema patentnom zahtjevu 6, naznačen time, da: (a) inhibitor kinaze tirozina je EGFR-inhibitor; (b) inhibitor kinaze serina/treonina je BRAF-inhibitor; i (c) kemoterapeutsko sredstvo je taksan.
8. ADC za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da rak je jedan rak koji eksprimira AXL.
9. ADC za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da je rak odabran od sljedećih: melanom, rak ne-malih stanica pluća (NSCLC), rak cerviksa, karcinom rožnatih stanica glave i vrata (SCCHN), rak dojke, gastrointestinalni stromalni tumor (GIST), renalni rak, rak prostate, neuroblastom, rak gušterače, rak jednjaka, rabdomiosarkom, akutna mijeloidna leukemija (AML), ili kronična mijeloidna leukemija (CML).
10. ADC za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se upotrebljava u kombinaciji s terapeutskim sredstvom, pri čemu se ADC i terapeutsko sredstvo primjenjuju istovremeno, odvojeno ili uzastopno.
11. ADC za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se upotrebljava u liječenju NSCLC koji je otporan na EGFR-inhibitorski agens, primjerice erlotinib.
12. ADC za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se upotrebljava u liječenju melanoma koji je otporan na vemurafenib.
13. ADC za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se upotrebljava u liječenju raka cerviksa koji je otporan na paklitaksel ili na njegov terapeutski djelotvoran analog ili derivat, kao primjerice docetaksel.
14. ADC za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da ADC obuhvaća citotoksični agens, kemoterapeutski lijek ili radioizotop povezan s protutijelom.
15. ADC za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da dio terapeutske skupine je citotoksični agens, prema potrebi povezan na ADC preko povezivača.
16. ADC za uporabu prema patentnom zahtjevu 15, naznačen time, da je citotoksični agens povezan s protutijelom preko povezivača koji se može cijepati, kao primjerice N-sukcinimidil-4-(2-piridilditio)-pentanoat (SSP), maleimidokaproil-valin-citrulin-p-aminobenziloksikarbonil (mc-vc-PAB) ili AV-1 K-lock valin-citrulin.
17. ADC za uporabu prema bilo kojem od patentnih zahtjeva 15 do 16, naznačen time, da je citotoksični agens povezan s protutijelom preko povezivača koji se ne može cijepati, kao primjerice sukcinimidil-4-(N-maleimidometil)cikloheksan-1-karboksilat (MCC) ili maleimidokaproil (MC).
18. ADC za uporabu prema bilo kojem od patentnih zahtjeva 15 do17, naznačen time, da je citotoksični agens odabran iz skupine koja se sastoji od DNK-ciljanih sredstava, naime DNK-alkilatora i križnih povezivača, kao primjerice kaliheamicin, duokarmicin, rahelmicin (CC-1065), pirolo[2,1-c][1,4]benzodiazepini (PBD-ovi), i indolinobenzodiazepin (IGN); sredstva koja ciljaju na mikrotubule, kao što je primjerice duostatin, duostatin-3, auristatin, primjerice monometilauristatin E (MMAE) i monometilauristatin F (MMAF), dolastatin, majtanzin, N(2')-deacetil-N(2')-(3-merkapto-1-oksopropil)-majtanzin (DM1), i tubulizin; te analozi nukleozida; ili njihovi analozi, derivati ili predlijekovi.
19. ADC za uporabu prema bilo kojem od patentnih zahtjeva 15 do18, naznačen time, da: (a) povezivač se može cijepati i citotoksični agens ima kapacitet uništenja nesudionika (engl. bystender); (b) povezivač se može cijepati i citotoksični agens nema kapacitet ubijanja nesudionika; (c) povezivač se ne može cijepati i citotoksični agens ima kapacitet ubijanja nesudionika; (d) povezivač se ne može cijepati i citotoksični agens nema kapacitet ubijanja nesudionika.
20. ADC za uporabu prema bilo kojem od patentnih zahtjeva 15 do 19, naznačen time, da je povezivač mc-vc-PAB i citotoksični agens je MMAE.
21. ADC za uporabu prema bilo kojem od patentnih zahtjeva 15 do 19, naznačen time, da povezivač je SSP i citotoksični agens je DM1.
22. ADC za uporabu prema bilo kojem od patentnih zahtjeva 15 do 19, naznačen time, da lijek je duostatin-3.
23. ADC za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da je sekvenca aminokiseline ljudskog AXL specificirana u SEQ ID br. 130.
24. ADC za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se veže na AXL majmuna cinomolgusa kao što je specificirano u SEQ ID br. 147.
25. ADC za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da protutijelo obuhvaća najmanje jedno područje vezanja koje sadrži VH područje koje je barem 90%, barem 95%, barem 97%, barem 99%, identično sa SEQ ID br. 1, i VL područje koje je barem 90%, barem 95%, barem 97%, barem 99%, identično sa SEQ ID br. 2 [107].
26. ADC za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da najmanje jedno područje vezanja sadrži VH područje koje obuhvaća SEQ ID br. 1 i VL područje koje obuhvaća SEQ ID br. 2 [107].
27. ADC za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da: protutijelo obuhvaća najmanje jedno područje vezanja koje sadrži VH područje sa sekvencama CDR1, CDR2 i CDR3 od SEQ ID br. 36, 37 odnosno 38; i VL područje sa sekvencama CDR1, CDR2 i CDR3 od SEQ ID br. 39, GAS odnosno 40 [107], povezivač je mc-vc-PAB, i citotoksični agens jeMMAE.
28. ADC za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se protutijelo veže s epitopom na AXL, pri čemu se epitop prepoznaje putem bilo kojeg od protutijela definiranog u patentnom zahtjevu 19.
29. ADC za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se protutijelo veže na epitop unutar domene Ig1 od AXL, dok epitop obuhvaća ili mu je potrebna jedna ili više aminokiselina koje odgovaraju pozicijama L121 do Q129 ili T112 do Q124 od ljudskog AXL.
30. ADC za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da protutijelo obuhvaća teški lanac od izotipa koji je odabran iz skupine koja se sastoji od sljedećih: IgG1, IgG2, IgG3 i IgG4.
31. ADC za uporabu prema patentnom zahtjevu 30, naznačen time, da izotip je IgG1, opcionalno alotip IgGlm(f).
32. ADC za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se radi o monoklonalnom protutijelu pune duljine, kao primjerice monoklonalnom protutijelu pune duljine IgG1,κ-protutijelu.
33. ADC za uporabu prema bilo kojem od patentnih zahtjeva 1 do 32, naznačen time, da protutijelo je protutijelo nedovoljne efektorske funkcije, stabilizirano IgG4-protutijelo ili monovalentno protutijelo.
34. ADC za uporabu prema patentnom zahtjevu 33, naznačen time, da je teški lanac modificiran tako, da je cjelokupno zglobno područje izbačeno.
35. ADC za uporabu prema bilo kojem od patentnih zahtjeva 33 i 34, naznačen time, da je sekvenca protutijela modificirana tako, da ona ne obuhvaća niti jedno prihvatno mjesto za N-povezanu glikozilaciju.
36. ADC za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se radi o protutijelu koje je protutijelo jednostrukog lanca.
37. ADC za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se radi o protutijelu koje je bispecifično protutijelo i koje sadrži prvo područje vezanja protutijela u skladu s bilo kojim od prethodnih patentnih zahtjeva, i drugo područje vezanja koje se veže na različiti cilj ili epitop, nego što je od prvog područja vezanja.
HRP20200551TT 2015-07-10 2016-07-08 Axl-specifični konjugati protutijelo-lijek za liječenje raka HRP20200551T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/EP2015/065900 WO2016005593A1 (en) 2014-07-11 2015-07-10 Antibodies binding axl
US201662278283P 2016-01-13 2016-01-13
PCT/EP2016/066353 WO2017009258A1 (en) 2015-07-10 2016-07-08 Axl-specific antibody-drug conjugates for cancer treatment
EP16739079.8A EP3319993B1 (en) 2015-07-10 2016-07-08 Axl-specific antibody-drug conjugates for cancer treatment

Publications (1)

Publication Number Publication Date
HRP20200551T1 true HRP20200551T1 (hr) 2020-07-10

Family

ID=57756861

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20200551TT HRP20200551T1 (hr) 2015-07-10 2016-07-08 Axl-specifični konjugati protutijelo-lijek za liječenje raka

Country Status (22)

Country Link
US (4) US20180326084A1 (hr)
EP (3) EP3319993B1 (hr)
JP (5) JP6892431B2 (hr)
KR (1) KR20180033523A (hr)
CN (3) CN108368171A (hr)
AU (3) AU2016292762B2 (hr)
CA (2) CA2991805A1 (hr)
CY (1) CY1123983T1 (hr)
DK (1) DK3319993T3 (hr)
EA (2) EA201890272A1 (hr)
ES (2) ES2784685T3 (hr)
HR (1) HRP20200551T1 (hr)
HU (1) HUE049072T2 (hr)
IL (2) IL256790B (hr)
LT (1) LT3319993T (hr)
ME (1) ME03772B (hr)
PL (1) PL3319993T3 (hr)
PT (1) PT3319993T (hr)
RS (1) RS60141B1 (hr)
SI (1) SI3319993T1 (hr)
SM (1) SMT202000359T1 (hr)
WO (2) WO2017009258A1 (hr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10512688B2 (en) 2014-07-11 2019-12-24 Genmab A/S Antibodies binding AXL
PL3319993T3 (pl) * 2015-07-10 2020-07-27 Genmab A/S Specyficzne wobec AXL koniugaty przeciwciało-lek do leczenia raka
ES2983242T3 (es) 2016-01-13 2024-10-22 Genmab As Formulación para anticuerpo y conjugado de fármaco del mismo
AU2017269335B2 (en) 2016-05-26 2021-07-01 Recurium Ip Holdings, Llc EGFR inhibitor compounds
WO2018007592A1 (en) 2016-07-08 2018-01-11 Genmab A/S New dosage regimens for antibody drug conjugates based on anti-axl antibodies
CN109715163B (zh) 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
JP7300394B2 (ja) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害
CA3057969A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
MX2020002553A (es) * 2017-09-08 2020-07-22 Hoffmann La Roche Metodos de diagnostico y terapeuticos para el cancer.
SG11202002331QA (en) * 2017-09-13 2020-04-29 Nat Res Council Canada Axl-specific antibodies and uses thereof
JP7681401B2 (ja) * 2018-04-10 2025-05-22 ジェンマブ エー／エス がん処置のためのａｘｌ特異的抗体
CN110483639A (zh) * 2018-05-15 2019-11-22 复旦大学 靶向axl的抗体及抗体-药物偶联物及其制备方法和用途
CN110540592B (zh) 2018-05-29 2022-08-09 杭州尚健生物技术有限公司 结合axl蛋白的抗体及其应用
WO2020065396A1 (en) * 2018-09-26 2020-04-02 Genmab A/S Axl-specific antibodies for treatment of non-small cell lung cancer
BR112021018611A2 (pt) * 2019-03-20 2021-11-23 Imcheck Therapeutics Sas Anticorpos tendo especificidade para btn2 e usos dos mesmos
EP3946453A4 (en) * 2019-03-29 2022-12-07 Celldex Therapeutics, Inc. ANTI-AXL ANTIBODIES AND THEIR METHODS OF USE
AU2020276695A1 (en) 2019-05-13 2021-12-23 Novartis Ag New crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as Raf inhibitors for the treatment of cancer
WO2021154156A1 (en) * 2020-01-31 2021-08-05 Agency For Science, Technology And Research Anti-axl antibody and uses thereof
PH12022552041A1 (en) 2020-02-28 2023-11-29 Servier Lab Anti-axl antibodies and compositions
EP4149472A1 (en) * 2020-05-12 2023-03-22 Novartis AG Therapeutic combinations comprising a craf inhibitor
WO2022026807A2 (en) * 2020-07-30 2022-02-03 Albert Einstein College Of Medicine Antibodies targeting sars-cov-2 and uses thereof
JP2023548600A (ja) * 2020-11-06 2023-11-17 デイ ワン バイオファーマシューティカルズ， インコーポレイテッド 低グレード神経膠腫を処置するためのｒａｆインヒビター
WO2024178140A1 (en) * 2023-02-22 2024-08-29 Resolute Science, Inc. Compositions and methods for targeting tumor-associated macrophages
WO2024178139A1 (en) * 2023-02-22 2024-08-29 Resolute Science, Inc. Compositions and methods for targeting tumor-associated macrophages

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US761218A (en) 1899-10-05 1904-05-31 U S Standard Voting Machine Co Register or counter.
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0486622T3 (da) 1989-08-09 1999-07-19 Rhomed Inc Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
CA2113113A1 (en) 1991-07-08 1993-01-21 Simon W. Kantor Thermotropic liquid crystal segmented block copolymer
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
AU2753100A (en) 1999-02-03 2000-08-25 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
HK1049014A1 (zh) 1999-07-29 2003-04-25 Medarex, Inc. 抗her2/neu的人類單克隆抗體
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
IL154183A0 (en) 2001-05-31 2003-07-31 Medarex Inc Cytotoxins, prodrugs, linkers and stabilizers useful therefor
ATE514717T1 (de) 2002-07-18 2011-07-15 Merus B V Rekombinante produktion von antikörpermischungen
HUE027549T2 (hu) 2002-07-31 2016-10-28 Seattle Genetics Inc Hatóanyagot tartalmazó konjugátumok és alkalmazásuk rák, autoimmun betegség vagy fertõzéses betegség kezelésére
AU2003282624A1 (en) 2002-11-14 2004-06-03 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
SG10201701737XA (en) 2003-11-06 2017-04-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
AU2006277117B2 (en) 2005-08-05 2013-01-10 Syntarga B.V. Triazole-containing releasable linkers and conjugates comprising the same
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1973576B1 (en) 2005-11-28 2019-05-15 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
BRPI0707426A2 (pt) 2006-02-02 2011-05-03 Syntarga Bv composto, conjugado, uso de um composto, composição farmacêutica, processo para preparar uma composição farmacêutica, e, métodos de tratamento de um mamìfero estando em necessidade do mesmo, e de tratamento ou prevenção de um tumor em um mamìfero
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
EP2070956A1 (en) 2007-12-14 2009-06-17 Total Petrochemicals Research Feluy Process for the production of a bimodal polypropylene having low ash content
CA2691434C (en) 2007-06-21 2020-07-21 Macrogenics, Inc. Covalent diabodies and uses thereof
EP2173739B1 (en) 2007-08-01 2013-07-31 Syntarga B.V. Substituted cc-1065 analogs and their conjugates
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
RU2506276C2 (ru) 2007-11-12 2014-02-10 УЗ ФАРМА ГмбХ Axl-антитела
CA2706549A1 (en) 2007-11-15 2009-05-22 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody capable of binding to anexelekto, and use thereof
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
JP5397668B2 (ja) 2008-09-02 2014-01-22 ソニー株式会社 記憶素子および記憶装置
US8889868B2 (en) 2008-11-03 2014-11-18 Syntarga Bv CC-1065 analogs and their conjugates
CA2745460C (en) 2008-12-19 2021-07-13 Macrogenics, Inc. Covalent diabodies and uses thereof
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
MX2011011825A (es) 2009-05-11 2011-12-06 U3 Pharma Gmbh Anticuerpos humanizados para axl.
KR20120024763A (ko) 2009-05-15 2012-03-14 추가이 세이야쿠 가부시키가이샤 항ａｘｌ 항체
SMT202100250T1 (it) 2009-06-26 2021-07-12 Regeneron Pharma Anticorpi bispecifici facilmente isolati con formato di immunoglobulina nativo
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
FI2560993T3 (fi) 2010-04-20 2024-09-23 Genmab As Heterodimeeristä vasta-ainetta FC sisältävät proteiinit ja menetelmät niiden tuottamiseksi
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
AR082017A1 (es) 2010-06-18 2012-11-07 Genentech Inc Anticuerpos anti-axl (receptor de tirosina quinasas) y metodos de uso
RU2608640C2 (ru) 2010-08-16 2017-01-23 Новиммун С.А. Способы получения мультиспецифичных и мультивалентных антител
CN103068847B (zh) 2010-08-24 2019-05-07 罗切格利卡特公司 可活化的双特异性抗体
KR101586128B1 (ko) 2010-08-24 2016-01-15 에프. 호프만-라 로슈 아게 디술피드 안정화 ― Ｆｖ 단편을 포함하는 이중특이적 항체
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
KR20140104944A (ko) 2011-06-22 2014-08-29 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 항-ａｘｌ 항체 및 그의 용도
EP2723377B1 (en) 2011-06-22 2018-06-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
EP2589609A1 (en) 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
US9879061B2 (en) 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
AU2012355415B2 (en) 2011-12-20 2017-07-06 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
SI2838917T1 (sl) 2012-04-20 2019-11-29 Merus Nv Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul
JP6239597B2 (ja) 2012-05-15 2017-11-29 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 薬物コンジュゲート、コンジュゲーション方法およびその使用
KR102167228B1 (ko) * 2012-11-05 2020-10-19 피에르 파브르 메디카먼트 새로운 항원 결합 단백질들 및 암의 치료를 위한 어드레싱 산물로서 그들의 용도
WO2014093707A1 (en) 2012-12-14 2014-06-19 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl signaling in primary tumor therapy
US20160097370A1 (en) * 2013-03-26 2016-04-07 James L. Rodgers High-torque wind turbine
US20160106861A1 (en) * 2013-04-26 2016-04-21 Spirogen Sarl Axl antibody-drug conjugate and its use for the treatment of cancer
WO2015161230A1 (en) * 2014-04-19 2015-10-22 Massachusetts Institute Of Technology Methods of reducing kinase inhibitor resistance
GB201410825D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
US10512688B2 (en) * 2014-07-11 2019-12-24 Genmab A/S Antibodies binding AXL
PL3319993T3 (pl) * 2015-07-10 2020-07-27 Genmab A/S Specyficzne wobec AXL koniugaty przeciwciało-lek do leczenia raka

Also Published As

Publication number Publication date
EA201891607A1 (ru) 2019-01-31
JP2022037170A (ja) 2022-03-08
JP2021138727A (ja) 2021-09-16
KR20180033523A (ko) 2018-04-03
PL3319993T3 (pl) 2020-07-27
HK1255412A1 (en) 2019-08-16
PT3319993T (pt) 2020-04-22
HUE049072T2 (hu) 2020-09-28
CN108884165A (zh) 2018-11-23
CY1123983T1 (el) 2022-03-24
CN108368171A (zh) 2018-08-03
IL256790B (en) 2021-06-30
JP2019509257A (ja) 2019-04-04
AU2022259847A1 (en) 2022-12-08
CN116617410A (zh) 2023-08-22
AU2022259847C1 (en) 2024-08-08
LT3319993T (lt) 2020-05-11
IL256790A (en) 2018-03-29
JP2018525354A (ja) 2018-09-06
ES3029907T3 (en) 2025-06-25
ES2784685T3 (es) 2020-09-29
IL260065A (en) 2018-07-31
CA2991805A1 (en) 2017-01-19
US20200397913A1 (en) 2020-12-24
RS60141B1 (sr) 2020-05-29
SMT202000359T1 (it) 2020-09-10
EP3402822C0 (en) 2025-03-12
EA201890272A1 (ru) 2018-08-31
WO2017009258A1 (en) 2017-01-19
EP3319993B1 (en) 2020-01-15
AU2017206967A1 (en) 2018-07-26
AU2016292762B2 (en) 2022-07-28
EP3730520A1 (en) 2020-10-28
EP3402822B1 (en) 2025-03-12
JP7428680B2 (ja) 2024-02-06
AU2016292762A1 (en) 2018-02-01
JP6892431B2 (ja) 2021-06-23
SI3319993T1 (sl) 2020-06-30
ME03772B (me) 2021-04-20
AU2017206967B2 (en) 2024-03-14
AU2022259847B2 (en) 2024-05-02
US20190022243A1 (en) 2019-01-24
US20230321261A1 (en) 2023-10-12
EP3402822A1 (en) 2018-11-21
CA3010887A1 (en) 2017-07-20
WO2017121877A1 (en) 2017-07-20
EP3319993A1 (en) 2018-05-16
DK3319993T3 (da) 2020-04-20
US20180326084A1 (en) 2018-11-15
JP2024038480A (ja) 2024-03-19

Similar Documents

Publication Publication Date Title
HRP20200551T1 (hr) Axl-specifični konjugati protutijelo-lijek za liječenje raka
JP2018525354A5 (hr)
Thomas et al. Antibody–drug conjugates for cancer therapy
JP2020525542A5 (hr)
Yao et al. Duocarmycin-based antibody–drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: pharmaceutical strategy and clinical progress
Nagayama et al. Antibody–drug conjugates for the treatment of solid tumors: clinical experience and latest developments
Lopus Antibody-DM1 conjugates as cancer therapeutics
CN110248963B (zh) 抗ccr7抗体药物缀合物
HRP20200283T1 (hr) Protutijela koja se vežu na axl
Sapra et al. Investigational antibody drug conjugates for solid tumors
RU2685728C2 (ru) Конъюгат лиганд - цитотоксическое лекарственное средство, способ его получения и его применения
JP2017522871A5 (hr)
AU2019320336B2 (en) Combination of antibody-drug conjugate and tubulin inhibitor
Govindan et al. Designing immunoconjugates for cancer therapy
JP2020526584A5 (hr)
HRP20191688T1 (hr) Cd37-vezujuće molekule i njihovi imunokonjugati
FI3930847T3 (fi) Korkea-affiinisia anti-MERTK-vasta-aineita ja niiden käyttöjä
SI2582728T1 (en) Human Antibodies Conjugates against a Tissue Factor
NZ707543A (en) Pyrrolobenzodiazepine-antibody conjugates
TW201116300A (en) DR5 Ligand Drug Conjugates
JP2014533954A5 (hr)
JP2023022328A5 (hr)
JP2008515889A5 (hr)
Wolska-Washer et al. Emerging antibody-drug conjugates for treating lymphoid malignancies
HRP20211152T1 (hr) Konjugati antitijela s lijekom koji ciljaju na uparap